Venture firms give OptiMedica $13.8 million

Santa Clara, CA-Ophthalmic therapeutic device developer Optimedica Corp. raised $13.8 in capital through a Series A and B financing co-led by Kleiner Perkins Caufield & Byers and Alloy Ventures.

"OptiMedica is committed to evolving the standards of care in ophthalmology," said David Mordaunt, PhD, OptiMedica chief executive officer. "This financing allows us to roll out technologies to support our mission, while we continue to build our world-class organization centered around our customers-the physician and, ultimately, the patient."